

Wednesday, 8 June 2005

FOR IMMEDIATE RELEASE

OBJ receives approval for Vaccine and Anti-body drug patch trials

=====

OBJ Limited (OBJ) is pleased to announce that it has received Ethics Committee approval to commence animal trials to investigate the efficacy of its Dermaportation drug delivery technology in the development of a Vaccine and Anti-body drug patch.

The approval provides OBJ with the ability to trial its technology as a means of delivering a number of key vaccines and anti-bodies through the skin, rather than by injection, as is currently the case.

Inter-dermal delivery of vaccines has been shown to be up to 6 times more efficient than intra-muscular injections. This would allow more people to be immunised using current vaccine stocks or less vaccine being needed by an individual to create the same immunological response.

Through-the-skin administration of drugs, vaccines and anti-bodies offers a number of additional commercial and social advantages, including over-the-counter distribution plus safe and simple self-administration. A vaccine patch would also reduce the need for sterile conditions, highly trained staff and safety concerns relating to needle stick injuries.

The vaccine and anti-body program will be conducted as an independent research program by Murdoch University, under the supervision of Dr Robin Jacobs.

The company expects initial results by October 2005.

- Ends -

OBJ
LIMITED

RESEARCH
SOLUTIONS
CORPORATION

Background to the Announcement

OBJ Limited is a drug delivery company, developing electronic "drug patch" technologies that allow drugs, therapeutic agents and cosmetic compounds to be delivered more effectively and more efficiently through-the-skin.

The company had previously announced a 600% increase in the rate of delivery of the drug caffeine and a 70% reduction in the through-the-skin delivery times for the anaesthetic drugs lignocaine and prilocaine hydrochloride. More recently, it had demonstrated precise control over drug delivery rates and recent finding added an additional time-based control mechanism previously not seen in the drug delivery sector.

OBJ maintains a continues development and discovery program that currently includes a number of commercially significant anti-inflammatory, anti-pain, anti-oxidant and anti-cancer drugs, as well as a number of cosmetic compounds.

Independence of Results

OBJ contracts its drug and technology testing programs to independent and respected organisations, such as Western Australian Biomedical Research Institute, Western Australian Institute for Medical Research, Curtin University of Technology and Murdoch University,

The high level of independence and international accreditation means that the results by OBJ can be published and presented at major medical and scientific conferences and forums.

For more information:

Jeffrey Edwards
Phone: +61 8 944 33011
Mobile: 041 791 2211
E-mail: jedwards@obj.com.au